TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:19
PUMA BIOTECHNOLOGY INC. ( PBYI ) https://www.pumabiotechnology.com
3.94USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-4.37%
PBYI
SPY
30.72%
-65.50%
PBYI
SPY
112.82%
-80.57%
PBYI
SPY
201.04%
-96.42%
PBYI
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
188.41
324.69
0.18
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
50.61
0.82
4.86
13.63
0.00
8.28
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
15.30
76.33
17.10
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.379
20.78
20.21
0.85
Other Earnings and Cash Flow Stats:
PUMA BIOTECHNOLOGY INC. ( PBYI ) Net Income TTM ($MM) is 1.24
PUMA BIOTECHNOLOGY INC. ( PBYI ) Operating Income TTM ($MM) is 32.62
PUMA BIOTECHNOLOGY INC. ( PBYI ) Owners' Earnings Annual ($MM) is -16.15
PUMA BIOTECHNOLOGY INC. ( PBYI ) Current Price to Owners' Earnings ratio is -11.77
PUMA BIOTECHNOLOGY INC. ( PBYI ) EBITDA TTM ($MM) is 43.33
PUMA BIOTECHNOLOGY INC. ( PBYI ) EBITDA Margin is 17.10%
Capital Allocation:
PUMA BIOTECHNOLOGY INC. ( PBYI ) has paid 0.00 dividends per share and bought back -2.251495 million shares in the past 12 months
PUMA BIOTECHNOLOGY INC. ( PBYI ) has increased its debt by 20.621 million USD in the last 12 months
Capital Structure:
PUMA BIOTECHNOLOGY INC. ( PBYI ) Interest-bearing Debt ($MM) as of last quarter is 139
PUMA BIOTECHNOLOGY INC. ( PBYI ) Annual Working Capital Investments ($MM) are 7
PUMA BIOTECHNOLOGY INC. ( PBYI ) Book Value ($MM) as of last quarter is 38
PUMA BIOTECHNOLOGY INC. ( PBYI ) Debt/Capital as of last quarter is 360%
Other Balance Sheet Stats:
PUMA BIOTECHNOLOGY INC. ( PBYI ) has 81 million in cash on hand as of last quarter
PUMA BIOTECHNOLOGY INC. ( PBYI ) has 67 million of liabilities due within 12 months, and long term debt 99 as of last quarter
PUMA BIOTECHNOLOGY INC. ( PBYI ) has 47 common shares outstanding as of last quarter
PUMA BIOTECHNOLOGY INC. ( PBYI ) has 0 million USD of preferred stock value
Academic Scores:
PUMA BIOTECHNOLOGY INC. ( PBYI ) Altman Z-Score is -6.73 as of last quarter
PUMA BIOTECHNOLOGY INC. ( PBYI ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
PUMA BIOTECHNOLOGY INC. ( PBYI ) largest shareholder is Geode Capital Management, LLC owning 425515 shares at 1.68 ($MM) value
Michael Patrick Miller(an insider) Sold 25000 shares of PUMA BIOTECHNOLOGY INC. ( PBYI ) for the amount of $70750.00 on 2023-11-07
15.16% of PUMA BIOTECHNOLOGY INC. ( PBYI ) is held by insiders, and 59.96% is held by institutions
PUMA BIOTECHNOLOGY INC. ( PBYI ) went public on 2012-04-24
Other PUMA BIOTECHNOLOGY INC. ( PBYI ) financial metrics:
FCF:13.17
Unlevered Free Cash Flow:31.03
EPS:0.48
Operating Margin:15.30
Gross Profit Margin:76.33
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:59.84
Beta:0.85
Buffet's Owners Earnings:-16.15
Price to Owner's Earnings:-11.77
About PUMA BIOTECHNOLOGY INC. ( PBYI ) :
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 (neratinib, oral), for the patients with early stage HER2-overexpressed/amplified breast cancer; for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; and for HER2 mutation-positive solid tumors. Its products also includes PB272 (neratinib, intravenous), and PB357. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.